Join Labcorp Drug Development and Median Technologies leaders in a stimulating conversation to learn how proven, modern, decentralized clinical trial (DCT) strategies will improve patient compliance and engagement, accelerate timelines, and decrease site burden.

This webinar is jointly organized by Labcorp Drug Development and Median Technologies. New Imaging biomarkers have a strong potential to provide additional insight for clinical trials: better selection of patients, prediction of response to therapy, early assessments of drug effects and safety. However, implementing them in clinical trials often promote challenges. The aim of this webinar is to discuss these challenges from the perspective of patients, physicians and the different stakeholders involved in the oncology clinical trials. Want to know more? Register now!

Investigator sites have an instrumental role in clinical trials, with endless responsibilities such as recruiting patients, acquiring, and submitting medical images to imaging CROs. Imaging CROs such as Median Technologies, will collect and review medical images to assess drug safety and efficacy based on the imaging endpoints. Efficient communication and streamlined processes between investigator sites and imaging CROs are key success factors for clinical trials in oncology. Want to know more? Watch the replay now!

Inter-reader variability can create challenges in oncology trial results. During this 45-minute presentation, Median Technologies addresses the 4 main causes of variability occurring during RECIST1.1 assessment and describes control strategies using data analytics and medical investigations. Want to know more? Watch the video now!

During our presentation, Labcorp and Median’s experts discuss modern imaging biomarkers covering the most important cancer hallmarks such as cell death, metabolism, vascularity, and hypoxia, and explain how they could be used in oncology trials for early response assessment and disease management.